A report on Tuesday from Zacks Investment Research upgraded VBI Vaccines (NASDAQ:$VBIV), Inc from a ‘Sell’ to a ‘Hold’ rating.

VBI Vaccines is a biotechnology company that specializes in developing vaccines and antigens for issues such as human cytomegalovirus. Their signature product is their eVLP vaccine platform that is designed to mimic viruses, with a second platform being a thermostable technology that enables the development of vaccines and biologics. They are headquartered in Cambridge, MA.

During trading on Tuesday, the company’s stock reached $3.87, representing a 1.28% upswing during day trading, with a trading volume of 10,821 shares. Their current market cap is $155.69 million. They had a 50-day and 200-day moving averages of $3.77 and $4.53. They also had a 52 week low of $2.75 and a 52 week high of $4.53.

Multiple other analytic firms have weighed in on the stock;

• TheStreet (NASDAQ:$TST), on May 31st, downgraded their rating from a ‘C-’ to a ‘D+’.
• ValuEngine, in a report from July 12th, increased their rating from a ‘Sell’ to a ‘Hold’.
• Noble Financial, on July 31st,  restated a ‘Buy’ rating.

The company has an aggregate of 2 ‘Buy’ ratings, 1 ‘Hold rating, and 1 ‘Sell’ rating, giving it an overall ‘Hold’ rating. It also holds a consensus price target of $5.38.

In insider news, CEO Jeff Baxter bought 10,000 shares for an average price of $3.28 per share and a total of $32,800.00, on August 10th. Baxter now owns 110,255 shares with an approximate value of $361,636.40. Altogether, 23,000 shares worth $74,510 were bought by insiders during the last quarter. Insider ownership accounts for 34.10% of the stock’s ownership.

Institutional investors have also recently modified their holdings in the stock;

• Teachers Advisors LLC bought roughly $195,000 worth of stock in the second quarter.
• Bank of New York Mellon Corp bought into the company with an opening purchase of $193,000 worth of stock in the second quarter.
• California State Teachers Retirement System bought into the company with a first-time purchase of $167,000 worth of shares in the second quarter.
• Schwab Charles Investment Management Inc. began investing in the company with a purchase of $187,000 worth of stock in the second quarter.
• Finally, Bank of Montreal Can (NYSE:$BMO) bought a new position in the company with an opening purchase of $164,000 worth of stock during the third quarter.

The company is now 31.52% owned by institutions and hedge fund investors.

Featured Image: Depositphotos/© baburkina